BANK VONTOBEL/CALL/NOVO NORDISK ADR B/150/0.1/20.12.24 | Market Closed - Deutsche Boerse AG 02:04:55 2024-07-16 pm EDT | ||
| 0.88 EUR | -3.30% |
|
| Current month | -17.76% | ||
| 1 month | -17.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.88 | -3.30% |
| 24-07-15 | 0.91 | -5.21% |
| 24-07-12 | 0.96 | +15.66% |
| 24-07-11 | 0.83 | -15.31% |
| 24-07-10 | 0.98 | +6.52% |
Delayed Quote Deutsche Boerse AG
Last update July 16, 2024 at 02:04 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD0HBH |
| ISIN | DE000VD0HBH7 |
| Date issued | 2024-02-16 |
| Strike | 150 $ |
| Maturity | 2024-12-20 (157 Days) |
| Parity | 10 : 1 |
| Emission price | 0.56 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.3 € |
|---|---|
| Lowest since issue | 0.48 € |
| Spread | 0.01 € |
| Spread % | 1.11% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
- Stock Market
- Warrants
- Warrant
